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Introduction: Severe infections in intensive care patients show high morbidity and mortality rates. Linezolid is an
antimicrobial drug frequently used in critically ill patients. Recent data indicates that there might be high variability
of linezolid serum concentrations in intensive care patients receiving standard doses. This study was aimed to
evaluate whether standard dosing of linezolid leads to therapeutic serum concentrations in critically ill patients.
Methods: In this prospective observational study, 30 critically ill adult patients with suspected infections received
standard dosing of 600 mg linezolid intravenously twice a day. Over 4 days, multiple serum samples were obtained
from each patient, in order to determine the linezolid concentrations by liquid chromatography tandem mass
spectrometry.
Results: A high variability of serum linezolid concentrations was observed (range of area under the linezolid
concentration time curve over 24 hours (AUC24) 50.1 to 453.9 mg/L, median 143.3 mg*h/L; range of trough
concentrations (Cmin) < 0.13 to 14.49 mg/L, median 2.06 mg/L). Furthermore, potentially subtherapeutic linezolid
concentrations over 24 hours and at single time points (defined according to the literature as AUC24 < 200 mg*h/L
and Cmin < 2 mg/L) were observed for 63% and 50% of the patients, respectively. Finally, potentially toxic levels
(defined as AUC24 > 400 mg*h/L and Cmin > 10 mg/L) were observed for 7 of the patients.
Conclusions: A high variability of linezolid serum concentrations with a substantial percentage of potentially
subtherapeutic levels was observed in intensive care patients. The findings suggest that therapeutic drug
monitoring of linezolid might be helpful for adequate dosing of linezolid in critically ill patients.
Trial registration: Clinicaltrials.gov NCT01793012. Registered 24 January 2013.Introduction
Severe infections in ICU patients remain a major challenge
in modern medicine. The prevalence of severe infections
such as sepsis or septic shock in ICU patients ranges from
20 to 80% with high mortality rates of 20 to 50% [1-5].
Consequently, there is a substantial need for optimizing
antimicrobial therapy. Key elements for the treatment of
infections include an adequate antimicrobial therapy
with an early initiation and with sufficiently high drug* Correspondence: Johannes.Zander@med.uni-muenchen.de
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unless otherwise stated.concentration levels [6-10]. Furthermore, sufficiently high
drug concentrations are required to limit the development
of antimicrobial resistance [11].
About 50% of bloodstream infections in critically ill
patients are caused by Gram-positive bacteria [12,13]. A
major part of these Gram-positive infections are repre-
sented by multidrug-resistant strains (for example,
methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci (VRE)), which are par-
ticularly frequent in ICUs [12-17]. Linezolid has good
in vitro and in vivo activity against these organisms and istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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critically ill patients [9,16,18-22]. The volume of distribu-
tion in adults of this hydrophilic antibiotic approximates
to the total body water content of 40 to 60 L [23]. The
plasma elimination half-life is mostly reported to be be-
tween 3.1 and 4.9 h with a clearance rate between 6.4 and
14.8 L/h [23]. Linezolid is metabolized by liver enzymes
to two major inactive metabolites, an aminoethoxyacetic
acid and a hydroxyethyl glycine, which are excreted pre-
dominantly - together with the parent substance - in
urine [24,25]. Because of its intrinsic chemico-physical
and pharmacokinetic characteristics, it is assumed that
adequate serum linezolid concentrations will be achieved
most of the time when using the recommended dose of
600 mg every 12 hours and that therapeutic drug monitor-
ing (TDM) might not be necessary [26,27]. This assump-
tion is based on reports showing adequate linezolid
concentrations in healthy volunteers or non-critically ill
patients [27-29]. According to the manufacturer, no dose
adjustment of linezolid is necessary in the case of renal or
liver impairment. Consequently, expert panels recommend
standardized doses of 600 mg linezolid twice a day also for
patients with severe infections such as sepsis or septic
shock [30]. However, 10 to 30% of critically ill patients re-
ceiving linezolid have treatment failure despite isolation of
Gram-positive organisms sensitive to linezolid [16,31,32].
Of these, 15 to 30% of patients suffer furthermore from
adverse effects such as elevated liver enzymes, gastrointes-
tinal disturbances or hematological toxicity [32-34]. The
rate of therapy failure and adverse effects may be in part
explained by a high variability of linezolid serum concen-
trations in critically ill patients.
Though there are have been few studies evaluating
blood levels and pharmacokinetic parameters of linezolid
in critically ill patients [26,35-41], it is still very difficult
for physicians to decide if therapeutic levels are reached
after standard dosing with linezolid when treating critic-
ally ill patients. The studies to date have found variable
results with regard to linezolid blood levels. A substan-
tial number demonstrated that inadequate levels occur
[36,37,39,41] whereas others concluded that standard
doses are mostly sufficient [35,38]. Low numbers of
study patients, the lack of use of compartment models, and
the retrospective design of most studies leave inconclusive
information about this topic within the existing literature.
Moreover, there are only preliminary data for linezolid
blood levels in specific subgroups of ICU patients, such
as critically ill patients on continuous renal replacement
therapy (CRRT), those on extracorporeal lung assist
(ECLA) and patients who have undergone organ trans-
plantation [41,42]. Indeed, most of these studies excluded
particular patient groups, therefore, do not represent the
full spectrum of different patients in ICUs. We therefore
designed a prospective observational study to analyze thevariability of linezolid serum concentrations in relation to
preliminary target concentration ranges in a heterogeneous
group of critically ill patients with suspected infections. The
primary aim of the study was to evaluate whether linezolid
serum concentrations in different critically ill patients were
within the defined therapeutic range.
Materials and methods
Patients
The study population originated from medical-surgical
critically ill patients hospitalized in two ICUs within the
Department of Anesthesiology, University Hospital of
Munich between March and November 2013. Patients
were eligible for inclusion if they had a severe infection
(confirmed or suspected by clinical assessment) and were
treated with linezolid intravenously by short-duration
infusions according to the clinic guidelines, and in ac-
cordance with the German Paul-Ehrlich-Society and the
guidelines of the Infectious Disease Society of America
[30,43]. Patients were only excluded if they were under
the age of 18 years, if their planned hospitalization was
less than 4 days, or if the first linezolid administration
was given more than 48 h before study enrollment.
Written informed consent was obtained from all patients
or their legal representatives.
Study design
The monocentric, prospective observational study was
performed at the University Hospital of Munich. The
study protocol (ClinicalTrials.gov, NCT01793012) was
approved by the Institutional Review Board of the
Medical Faculty of the Ludwig-Maximilians-University
(registration number 428-12) and carried out according to
the principles of the Declaration of Helsinki. Enrolled
patients (n = 30) received 600 mg linezolid twice a day
by short-duration infusion (15 to 60 minutes). Day 1 of
the study was defined as that day on which the first linezo-
lid trough level (Cmin) was determined (see Additional
file 1). This was directly before the second or third linezo-
lid administration in all patients except patients 2 and 27,
for whom the study start was directly before the fifth and
fourth linezolid administration, respectively. Serum sam-
ples from the arterial line for antibiotic determination
were collected at multiple time points before (Cmin), dur-
ing, and after the two linezolid administrations on day 1;
and before, during, and after one of the two linezolid
administrations on days 2, 3 and 4 (in total 26 to 43
samples per patient). The exact time of blood sampling was
recorded by the medical staff. Samples were immediately
sent to the Institute of Laboratory Medicine, University
Hospital of Munich, centrifuged (3,000 g, 10 minutes)
and aliquoted into 2-ml polypropylene tubes (Eppendorf,
Hamburg, Germany). Serum aliquots were stored within
one hour after blood sampling at −80°C.
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Clinical patient data and diagnosis in the ICU were re-
corded. Sepsis was defined according to the Society of
Critical Care Medicine/European Society of Intensive
Care Medicine (SCCM/ESICM) Consensus Conference
Committee [10]. The severity of the patient’s clinical
condition was characterized using the acute physiology
and chronic health evaluation (APACHE) II score. To
assess renal function, creatinine concentrations in both
serum and 24-h urine samples were determined using
an enzymatic photometric test on an automated chemistry
analyzer (Model AU5822: Beckmann Coulter, Brea, CA,
USA). Creatinine clearance (CLcrea) was calculated using
the formula:
CLcrea ¼ Curine  Vurineð Þ : Cserum  timeð Þ;
where Curine is the creatinine concentration in urine,
Vurine is the urine volume, and Cserum is the serum creatin-
ine concentration.
Determination of linezolid concentrations
Serum linezolid concentrations were determined using a
previously described liquid chromatography tandem mass
spectrometry (LC-MS/MS) method [44]. Briefly, sample
preparation was based on protein precipitation and on-line
solid phase extraction with two-dimensional liquid chroma-
tography and column switching. Three-fold deuterated li-
nezolid was used as the internal standard. Control samples
were used from both a commercial provider and from in-
house production. Validation revealed good analytical per-
formance showing inaccuracy <6% and imprecision <7.3%
(coefficient of variation) for all quality control samples. The
lower limit of quantification was 0.13 mg/L. The method
was found to be robust over the course of the study.
Pharmacokinetic analysis
We analyzed linezolid plasma concentrations with a com-
partmental pharmacokinetic model based on nonlinear
mixed-effects modeling. For model estimation we used the
NONMEM 7.2® program (Icon Development Solutions,
Hanover, MD, USA) with the FOCE-I estimation algorithm.
The aim of the pharmacokinetic analysis was to determine
individual concentration time courses. We assumed that
the population parameters were log-normally distributed.
The individual post-hoc concentration predictions ob-
tained from NONMEM were used to predict the time
course of linezolid plasma concentrations and to
calculate the area under the concentration time curve
over 24 h (AUC24)-values. Model selection was based
on the NONMEM objective function, goodness-of-fit
plots, and median absolute performance errors as
described by Varvel et al. [45]. For graphical analysis
we used PLTTools 5.0 PLTsoft, San Francisco,
CA USA [46]. Linezolid plasma concentrations werecalculated for each patient based on individual phar-
macokinetic parameters in 10-minute steps.
Assessment of target concentration ranges
The thresholds for potential therapeutic efficacy were
defined as Cmin >2 mg/L and/or AUC24 > 200 mg*h/L.
The rationale behind these two thresholds was the findings
of Rayner et al., showing a higher therapeutic success in
seriously ill patients when linezolid exceeds the minimum
inhibitory concentration (MIC) over the entire dosing
interval or when AUC24/MIC-values are higher than 80 to
120 [31]. We defined the MIC as the concentration
that inhibits the growth of 90% of important relevant
infectious pathogens (MIC90) (particularly S. aureus
and Enterococcus species) [47,48] and therefore, we set
the threshold of potential therapeutic efficacy of Cmin at
2 mg/L. As in Rayner et al., we set the AUC24/MIC90
value at 100, corresponding to a threshold for potential
therapeutic efficacy of AUC24-values of 200 mg*h/L. The
threshold for potential therapeutic toxicity was defined
as trough levels >10 mg/L or AUC24 values >400 mg*h/L
according to the literature [23,26,34].
Statistics
The AUC24 was calculated by means of the trapezoidal
rule using concentration values as predicted by the phar-
macokinetic model (individual post-hoc concentration
time course). Patients were divided into three groups in
relation to the defined target concentration ranges based
on their Cmin- and AUC24-values. Non-continuous pa-
rameters were expressed as percentages and numbers,
and compared by means of the Chi-square test. Continu-
ous parameters were expressed as median values and
ranges, and compared by the Jonckheere-Terpstra test.
A P-value below 0.05 was considered statistically significant.
All calculations were performed using SAS (version 9.3,
SAS Institute Inc., Cary, NC, USA).
Results
Twenty male and ten female patients with a median age
of 57 years (range, 28 to 84 years) and a median body
mass index (BMI) of 25.5 kg/m2 (range, 16 to 35 kg/m2)
were included. The most frequent causes of sepsis were
pneumonia and peritonitis (Table 1). Ten patients were
lung-transplant, and five were liver-transplant recipients.
Patients had high variability in APACHE II scores
(range 9 to 37, median 27.5). Of the 25 patients who
were not on CRRT, 5 had a reduced creatinine clearance
of <50 ml/minute. Five patients were being treated with
CRRT and seven patients were treated with ECLA. De-
tailed parameters of the corresponding CRRT and ECLA
systems are shown in Additional files 2 and 3.
Linezolid plasma concentrations were best described by
a two-compartment model with an individual (post-hoc)
Table 1 Characteristics of the study population




CRRT (+/−) ECLA (+/−) Organ transplantationb Clinical condition
1 20 89 - + Lung Septic pneumonia
2 12 129 - - - ARDS
3 20 21 - - - Septic peritonitis
4 28 114 - - - Septic pleural empyema
5 23 97 - + - ARDS
6 33 72 - + - Septic pneumonia
7 9 117 - - Lung Septic pneumonia
8 28 119 - - Lung Septic pneumonia
9 28 - + - Liver Septic peritonitis
10 29 94 - - - Septic pneumonia
11 33 35 - - Lung Septic pneumonia
12 31 102 - + - Septic pneumonia
13 14 127 - - - Septic pneumonia
14 14 69 - - Lung Septic pneumonia
15 32 42 - - - Septic endocarditis
16 19 76 - + - Septic pneumonia
17 35 - + - Liver Septic peritonitis
18 21 33 - - Lung Septic pneumonia
19 27 55 - - Lung Septic pneumonia
20 17 64 - - Lung Septic pleural empyema
21 30 68 - - - Septic pneumonia
22 23 - + - Liver Septic peritonitis
23 14 85 - - Liver Septic peritonitis
24 24 - + - Liver Septic peritonitis
25 37 74 - - Lung Septic pneumonia
26 25 83 - + Lung Septic pneumonia
27 28 - + - - Septic peritonitis
28 34 163 - + - Septic pneumonia
29 32 126 - - - ARDS
30 29 37 - - - Septic peritonitis
Median 27.5 83
(range) (9 to 37) (21 to 163)
aMean value of the 4 study days; bwithin the last 28 days. APACHE II, acute physiology and chronic health evaluation II score; CRRT, continuous renal replacement
therapy; ECLA, extracorporeal lung assist; ARDS, acute respiratory distress syndrome.
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prediction error of 13%. The parameter estimates (stand-
ard error) of the population model were: volume of dis-
tribution of the first compartment = 19.3 (3.9) L, volume
of distribution of the second compartment = 26.4 (3.8) L,
elimination clearance = 8.3 (0.9) L/h and inter-compart-
mental clearance = 56.0 (19.3) L/h.
Figure 1 shows the concentration time curves of
serum linezolid for each patient. A high inter-patient
variability was observed. The high inter-patient variability
could be quantified when AUC24-values ranged from 50.1to 453.9 mg*h/L (median 143.3 mg*h/L) (Table 2). The
high inter-patient variability was also observed for single
Cmin-values (range >100-fold, from <0.13 to 14.49 mg/L,
median 2.06 mg/L) (Table 2). To obtain further informa-
tion about the usefulness of cmin-values for TDM, Cmin
values were correlated with corresponding AUC24 values
giving an r2 value of 0.79 (Additional file 4).
In addition to the inter-patient variability, high intra-
patient variability of Cmin values was also observed. Nine
of thirty patients had maximum Cmin values, more than
































Patients 1-5 Patients 6-10
Patients 11-15 Patients 16-20
Patients 26-30Patients 21-25
Upper and lower limit of therapeutic range for linezolid trough levels
Figure 1 Serum concentration profiles of the 30 study patients. Serum concentrations over the course of 4 days, as measured by liquid
chromatography tandem mass spectrometry are shown.
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Table 2 Linezolid pharmacokinetic parameters following
intravenous administration of 600 mg twice daily in
critically ill ICU patients


































Range 50.1 to 453.9 <0.13 to 14.49
aAs determined by the NONMEM system, values from the start of the third
administration of linezolid over 24 h; bas analyzed by liquid chromatography
tandem mass spectrometry, values obtained directly before the fourth
administration of linezolid if not indicated otherwise;
cvalue obtained directly before the fifth administration of linezolid. AUC24,
concentration time curve over 24 h; Cmin, linezolid trough level.
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also Additional file 5). The Cmin of most patients did not
change in a consistent pattern over the 4 days of the
study; only in patients 3, 14, 18 and 25 did we observe
an increase, and in patient 4 a decrease of Cmin values
over time (Figure 1).Optimal pharmacodynamic exposure over 24 h with
AUC24 values between 200 and 400 mg*h/L and at a sin-
gle time point with Cmin values between 2 and 10 mg/L
was observed in 30% and 43% of the patients, respectively
(Table 3, Figure 1). Regarding these AUC24 and Cmin
values, 63% and 50% of the study patients had linezolid
concentrations below the lower limit of the corresponding
target concentration range, respectively, and 7% had linez-
olid concentrations above the target concentration range.
Moreover, only 17% of the patients continuously attained
optimal Cmin values between 2 and 10 mg/L over 4 days
(see Additional file 5).
Patients on CRRT had significantly higher Cmin values
and AUC24 values than patients without CRRT (P = 0.005
for AUC24 and P = 0.001 for Cmin) (Table 3). Similarly,
patients who had undergone liver transplantation had
significantly higher AUC24 and Cmin values than in
non- (liver and lung) transplant patients (P = 0.036 for
AUC24 and P = 0.012 for Cmin). Other characteristics
such as gender, lung transplantation and therapy with
ECLA did not have any significant influence on AUC24
or Cmin values. Variability of linezolid levels was high
in patient groups on CRRT and ECLA, and in the liver
and lung transplantation groups, with each group
showing a substantial proportion (≥40%) outside the
target concentration range. The distributions of continu-
ous parameters in relation to linezolid target ranges are
shown in Table 4. A trend towards higher linezolid serum
levels was observed in patients with reduced creatinine
clearance, although these changes were not significant
(P = 0.102 for Cmin and P = 0.051 for AUC24) (Table 4,
Additional file 6). Other continuous parameters such
as age, BMI, and APACHE-II score did not have any
significant influence on AUC24 or Cmin values.
Discussion
This study shows that the recommended standard dosing
of linezolid leads to subtherapeutic linezolid plasma
concentrations in about every second critically ill pa-
tient. Furthermore, a high variability of linezolid levels
was observed in the study population with a majority
(57 to 70%) detected outside the target ranges. Although
there were insufficient levels in the majority of patients,
inappropriate high levels occurred in a small number of
patients. Finally, this variability of linezolid levels was not
only observed between the different patients, but also
within individual patients over the course of 4 days.
Our findings are in line with other studies also ob-
serving very low AUC24 or Cmin values with the majority
being insufficient [37,39,41]. In contrast to some other
studies [37,39], we used two different approaches to de-
fine the lower threshold of the target range. First, we
used AUC24/MIC in concordance with other studies
[26,35,36,38,40,41], which was shown to be the best
Table 3 Distribution of patients in relation to the target range of linezolid






<200 200 to 400 >400 <2 2 to 10 >10
Total patients, n =30 19 (63) 9 (30) 2 (7) 15 (50) 13 (43) 2 (7)
Male patients, n = 20c 13 (65) 5 (25) 2 (10) 11 (55) 7 (35) 2 (10)
Female patients, n = 10 6 (60) 4 (40) 4 (40) 6 (60)
On CRRT, n = 5d 2 (40) 1 (20) 2 (40) 3 (60) 2 (40)
Not on CRRT, n = 25 17 (68) 8 (32) 15 (60) 10 (40)
On ECLA, n = 7c 5 (71) 2 (29) 5 (71) 2 (29)
Not on ECLA, n = 23 14 (61) 7 (30) 2 (9) 10 (43) 11 (48) 2 (9)
After liver transplantation, n = 5f 2 (40) 1 (20) 2 (40) 3 (60) 2 (40)
After lung transplantation, n = 10c 6 (60) 4 (40) 6 (60) 4 (40)
No transplantation, n = 15 11 (73) 4 (27) 9 (60) 6 (40)
aAs determined by the NONMEM system, values from the start of the third administration of linezolid; bas determined by liquid chromatography tandem mass
spectrometry, values obtained directly before the fourth administration of linezolid; cno significantly different values in comparison to the corresponding patient
group; dsignificantly higher values in patients on CRRT than in those not on CRRT (P <0.01); fsignificantly higher values in patients with liver transplantation than
in non-liver-transplant patients (P <0.05). AUC24, concentration time curve over 24 h; Cmin, linezolid trough level; CRRT, continuous renal replacement therapy;
ECLA, extracorporeal lung assist.
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approach 63% of our study patients had insufficient
linezolid serum levels. Second, we used Cmin values as
a further lower threshold of the target concentration
range, as time above the MIC over the entire dosing





<200 200 to 400
Mean creatinine clearance (mL/minute)c
median 89 62
range 35 to 163 21 to 117
(number of patients) (17) (8)
APACHE II score
median 28 24
range 12 to 37 9 to 33
(number of patients) (19) (9)
Age (years)
median 53 59
range 28 to 77 34 to 84
(number of patients) (19) (9)
Body mass index (kg/m2)
median 24 19
range 13 to 32 17 to 26
(number of patients) (19) (9)
aAs determined by the NONMEM system, values from the start of the third adminis
spectrometry, values obtained directly before the fourth administration of linezolid;
Cmin, linezolid trough level; APACHE II, acute physiology and chronic health evaluatwas set at 2 mg/L in accordance with MIC90 values of
relevant causative pathogens [47,48] as had been done
in other studies [26,37,39]. Different efficacy thresh-
olds might be used in environments where MIC90
values of relevant pathogens differ from 2 mg/L. Indeed,
linezolid serum concentrations during infection shouldlinezolid target ranges
edian and range of patients
Cmin (mg/L)
b
>400 <2 2 to 10 >10
89 70
35 to 163 21 to 117
(15) (10)
32 28 24 32
28 to 35 12 to 37 9 to 33 28 to 35
(2) (15) (13) (2)
56 57 57 56
50 to 61 28 to 77 29 to 84 50 to 61
(2) (15) (13) (2)
21 22 23 21
19 to 23 13 to 32 17 to 28 19 to 23
(2) (15) (13) (2)
tration of linezolid; bas determined by liquid chromatography tandem mass
cmean value of the 4 study days. AUC24, concentration time curve over 24 h;
ion II.
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ensure efficacy. This might be particularly important, as
the identity of most causative pathogens is unknown in
the early course of severe infection.
Furthermore, we showed that there is a high variability
of linezolid AUC24 and Cmin values with Cmin values dif-
fering more than 100-fold between the different study
patients and more than 30-fold within individual patients.
This is in line with some recent studies also describing
high variability of Cmin values differing more than 50-fold
between different patients [26,34,41]. In fact, the majority
of linezolid concentrations in our study was outside the
defined linezolid target concentration ranges, supporting
the concept of TDM. We set the upper threshold of the
target concentration range for Cmin values at 10 mg/L.
This was done in accordance with other studies, because
higher concentrations have been shown to be associated
with drug-related toxicity [23,26,34], whereas Pea at al.
showed that in long-term treatment with linezolid an
upper threshold of the target concentration range of
7 mg/L should be favored [49]. Indeed, in the study of Pea
et al., all patients with Cmin values >10 mg/L of linezolid
had substantial platelet reduction (>30%) during long-
term linezolid treatment, whereas no patient had these ad-
verse effects with Cmin values <4 mg/L. Despite the rather
high upper threshold used in our study, 7% of the patients
had linezolid concentrations above the target range. The
fact that for critically ill patients, the two parameters
AUC24/MIC >80 to 120 and time above MIC over the
entire dosing interval strongly correlated with treatment
efficacy [31], and that elevated linezolid concentrations
correlated with adverse effects [23,34], show that both
AUC24 and Cmin values correlate with efficacy and toxicity.
This strongly supports the concept of linezolid target
concentration ranges in terms of TDM. The good linear
relationship between Cmin and AUC24 values described
by Pea et al. [26] was confirmed in our study (r2 = 0.79).
Cmin might therefore be a useful parameter for TDM of
linezolid in clinical practice. As a high variation of Cmin
values within individual patients was observed in this
study, we would recommend repetitive determinations
of linezolid Cmin values during infection treatment.
Finally, the linezolid serum concentrations in different
critically ill patients, such as those on CRRT or ECLA,
and patients who had undergone liver or lung trans-
plantation, were evaluated. Only a few studies have
evaluated the pharmacokinetics of linezolid in critically
ill patients on CRRT [50-53], thereby using different
CRRT systems such as continuous venovenous hemo-
diafiltration (CVVHDF) and continuous venovenous
hemofiltration (CVVH). Linezolid concentrations were
partly subtherapeutic and partly within the potential
therapeutic range, however, a comparison of linezolid
levels in patients not on CRRT was not performed. Inour study, linezolid concentrations were tested in patients
with CVVHDF and CVVHD. In comparison to the other
study patients, significantly higher linezolid levels were
observed in patients on CRRT. However, it should be
noted that four of the five patients on CRRT were liver
transplant recipients and that higher levels of linezolid
have been reported in patients after liver transplantation
[41]. About 50% of the parent substance linezolid is
metabolized by liver enzymes to two major inactive
metabolites and are excreted predominantly - together
with linezolid - in urine [25]. Higher levels of linezolid
in patients after liver transplantations might therefore
be due to alterations in the activity of liver enzymes
after ischemia/reperfusion [41]. Higher numbers of pa-
tients on CRRT and those after liver transplantations with
simultaneous evaluation of the liver function, as well as of
linezolid and its inactive metabolites in urine will be ne-
cessary to definitely understand the impact of CRRT and
liver transplantations on linezolid concentrations in critic-
ally ill patients. Furthermore, we evaluated linezolid levels
in patients after lung transplantation and patients on
ECLA, and no significant differences (in the setting used
in our study) in comparison to the whole study population
were observed. Admittedly, the majority of the linezolid
levels were also insufficient in these patients. This is in
line with the reported low linezolid levels in three critically
ill patients on extracorporeal membrane oxygenation-
systems (specific ECLA system) and three critically ill
patients after lung transplantation [42,50], which are
the only available data on these patients.
The results of this study suggest that the limited
availability of linezolid quantification methods in clin-
ical laboratories might pose a serious problem for the
antimicrobial therapy of ICU patients. The reason for
the limited availability of such methods is in particular the
lack of cost-efficient commercially available linezolid
quantification tests. Only a few laboratories use custom-
made linezolid quantification methods such as high
performance liquid chromatography with UV-detection
(HPLC-UV) or LC-MS/MS. Development and routine use
of these custom-made methods require a high level of
human resources, professional specialization and high-
technology equipment, which can often only be provided
by large or specialized laboratories. The availability of
commercial quantification tests (for example, based on
HPLC-UV or immunoassay methods) of a therapeutic
substance applied in life-threatening conditions might
therefore be of particular impact.
The present study considered a number of aspects
which have only partially been covered in previous work:
(a) we investigated numerous critically ill patients from
the whole intensive care spectrum, including patients who
had undergone lung and liver transplantation and during
CRRT and ECLA; (b) we analyzed a large number of
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individual concentration time courses by pharmacoki-
netic modeling with a small median prediction error of
1% and a small median absolute prediction error of 13%;
(c) finally, this study used a highly accurate method for
linezolid quantification [44]. All other studies measuring
linezolid concentrations in critically ill patients used
HPLC-UV [26,35-41], which may be prone to interfer-
ence, especially in critically ill patients with extended
co-medication. In contrast, we used an LC-MS/MS
method, thereby, for the first time, using isotope dilution
internal standardization. As target analytes and internal
standards are very similar in their physico-chemical
properties, variances of individual samples impacting the
ionization are compensated almost completely, realizing
the highest attainable level of reliability [54]. Furthermore,
the use of control samples from both a commercial pro-
vider and from in-house production additionally ensures
the accuracy of the method. Indeed, there were only min-
imal undulations in the concentration-time curves of
linezolid in individual patients (Figure 1), showing that the
study-protocol, including blood sampling and analytical
method, was accurately performed.
The high variability of linezolid levels found in our
study, with a substantial proportion at insufficient low
levels, might contribute to the observed high mortality
rate and severity of infection in ICU patients. Further-
more, high variability of linezolid levels may also lead to
the development of resistance and drug-related toxicity.
As early and effective antimicrobial therapy has a substan-
tial effect on bacterial eradication and patient survival
[6,31], optimal individual dosing of antibiotics is of
particular importance. Given the fact that the most
common cause of death in the ICU in medically advanced
nations is severe infection [55] and because of worldwide
intentions to reduce morbidity and mortality from sepsis
[10], we believe that there is great importance in optimiz-
ing individual antimicrobial dosing with the aid of TDM.
Conclusions
We found high variability in linezolid serum concentrations
with mostly insufficient low levels in critically ill patients.
We therefore suggest general TDM of linezolid in critically
ill patients during linezolid therapy. However, future studies
will have to investigate whether application of TDM can
definitely improve linezolid-dosing protocols and infection-
related patient outcome.
Key messages
 High variability of linezolid serum concentrations
after standard linezolid dosing in 30 different
critically ill patients with suspected infections were
observed. We observed potentially subtherapeutic levels in the
majority of different patients.
 Potentially toxic levels were observed in a minority
of different patients.
 Our data suggests that therapeutic drug monitoring
might be helpful for adequate dosing of linezolid in
critically ill patients.
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